OSI Pharmaceuticals
OSI Pharmaceuticals, Inc. was an American pharmaceutical company formerly based on Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. On Sunday, May 16, 2010 OSI agreed to be acquired by Japan-based, TSE-listed Astellas Pharma for $4.0 billion. The deal was closed on June 9, 2010. The company closed its last facilities on Long Island in May 2013. OSI had specialized in the discovery and development of molecular targeted therapies. Though oncology was the top priority for OSI, research and development targeting type 2 diabetes and obesity was conducted through their U.K. subsidiary . OSI has also made a foray into the ophthalmology market through a marketing agreement with Pfizer over Macugen (Pegaptanib) for Age-related macular degeneration; however, acqu
Wikipage disambiguates
primaryTopic
OSI Pharmaceuticals
OSI Pharmaceuticals, Inc. was an American pharmaceutical company formerly based on Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. On Sunday, May 16, 2010 OSI agreed to be acquired by Japan-based, TSE-listed Astellas Pharma for $4.0 billion. The deal was closed on June 9, 2010. The company closed its last facilities on Long Island in May 2013. OSI had specialized in the discovery and development of molecular targeted therapies. Though oncology was the top priority for OSI, research and development targeting type 2 diabetes and obesity was conducted through their U.K. subsidiary . OSI has also made a foray into the ophthalmology market through a marketing agreement with Pfizer over Macugen (Pegaptanib) for Age-related macular degeneration; however, acqu
has abstract
OSI Pharmaceuticals, Inc. meru ...... as Pharma senilai $4.0 miliar.
@in
OSI Pharmaceuticals, Inc. was ...... hibitor intellectual property.
@en
founding year
industry
location
net income ($)
number of employees
parent company
product
revenue ($)
type
Link from a Wikipage to an external page
Wikipage page ID
11,662,608
page length (characters) of wiki page
Wikipage revision ID
1,019,617,119
Link from a Wikipage to another Wikipage
date
2002-09-21
foundation
industry
key people
Colin Goddard, CEO
@en
Michael G. Atieh, CFO
@en
Robert A. Ingram, Chairman
@en
Location
logo
@en
logo size
name
OSI Pharmaceuticals, Inc.
@en
net income
$-582.2 Million USD
@en
num employees
parent
products
Biotherapeutics
@en
revenue
$375.7 MillionUSD
@en
title
OSI Pharmaceuticals
@en
type
wikiPageUsesTemplate
wordnet_type
subject
comment
OSI Pharmaceuticals, Inc. meru ...... rakhir dengan divestasi saham.
@in
OSI Pharmaceuticals, Inc. was ...... ar degeneration; however, acqu
@en
label
OSI Pharmaceuticals
@en
OSI Pharmaceuticals
@in
seeAlso
wasDerivedFrom
isPrimaryTopicOf
name
OSI Pharmaceuticals, Inc.
@en